Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 82Cisplatin 52Oxaliplatin 36lenvatinib 24durvalumab 22Capecitabine 22Fluorouracil 20Leucovorin 15tislelizumab 11pembrolizumab 10apatinib 10Radiotherapy 10Albumin-Bound Paclitaxel 10Radiofrequency Ablation 9Magnetic Resonance Spectroscopy 9Irinotecan 9Floxuridine 9Liver Transplantation 8Drug Therapy 8Cholangiopancreatography, Endoscopic Retrograde 8130-nm albumin-bound paclitaxel 8Taxes 7Platinum 7Photochemotherapy 7Panitumumab 7Biopsy 71,2-diaminocyclohexaneplatinum II citrate 7tremelimumab 6pemigatinib 6camrelizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cholangiocarcinoma × ricolinostat × Clear all
NCT02856568 2017-05-30

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡